Voyager Therapeutics is trading at $2.00, up 5.00%, during the October 19 session, in line with a biotech-sector rally; no clear Voyager-specific announcement explaining the gain was found.
- XBI is up 2.09%, supported by biotech M&A activity and anticipation of cancer data.
- Merck KGaA’s announced $1.3 billion acquisition of Silence Therapeutics added to sector deal activity but was not a Voyager-specific catalyst.